Retatrutide
Definition: An investigational triple incretin receptor agonist being studied for obesity, fatty liver disease, and metabolic dysfunction.
What is Retatrutide?
Retatrutide is an investigational peptide agonist designed to activate three metabolic hormone receptors: GIP, GLP-1, and glucagon. It belongs to the next generation of multi-incretin therapies intended to combine appetite suppression, improved insulin secretion, and increased energy expenditure in one long-acting molecule.
How does Retatrutide work?
Retatrutide combines GLP-1-mediated satiety and glucose regulation with GIP activity and controlled glucagon receptor activation. Glucagon receptor signaling can increase energy expenditure and hepatic lipid metabolism, while GLP-1 and GIP components help counterbalance hyperglycemia risk by improving insulin secretion and appetite control.
Primary Documented Uses
- Investigational obesity treatment in clinical trials
- Research into metabolic dysfunction and fatty liver disease
- Study model for multi-incretin receptor biology
- Potential future cardiometabolic-risk reduction research
Research Summary
Phase 2 studies report striking mean weight reductions in adults with obesity and show dose-responsive metabolic improvements. Early trials also suggest potential benefit for liver-fat reduction in metabolic dysfunction-associated steatotic liver disease, though larger Phase 3 trials are required to define long-term safety, durability, and cardiovascular outcomes.
Legal and Regulatory Status
Retatrutide is not FDA-approved and remains an investigational drug. It should only be used in regulated clinical trials or authorized research settings.
Frequently Asked Questions
What is Retatrutide?
Retatrutide is An investigational triple incretin receptor agonist being studied for obesity, fatty liver disease, and metabolic dysfunction.
How does Retatrutide work?
Retatrutide combines GLP-1-mediated satiety and glucose regulation with GIP activity and controlled glucagon receptor activation. Glucagon receptor signaling can increase energy expenditure and hepatic lipid metabolism, while GLP-1 and GIP components help counterbalance hyperglycemia risk by improving insulin secretion and appetite control.
What does research say about Retatrutide?
Phase 2 studies report striking mean weight reductions in adults with obesity and show dose-responsive metabolic improvements. Early trials also suggest potential benefit for liver-fat reduction in metabolic dysfunction-associated steatotic liver disease, though larger Phase 3 trials are required to define long-term safety, durability, and cardiovascular outcomes.
Is Retatrutide FDA-approved or legally available?
Retatrutide is not FDA-approved and remains an investigational drug. It should only be used in regulated clinical trials or authorized research settings.